The mRNA is packaged inside in tiny fatty particles that protect it and assist it enter the organs. The medicine is given in a vein (IV). Because the mRNA doesn’t last lengthy, the medicine would need to be given on a regular schedule for the patient’s body to keep making the lacking enzyme. The results of the drugs had been evaluated in experimental models. No clinical trials with the medicine in patients with [ glycogen support](http://users.atw.hu/nlrp-verseny/index.php?PHPSESSID=ecf3498d7bee85b6f90d751418e4001e&action=profile